Journal article
Stress, mental disorder and ketamine as a novel, rapid acting treatment
European Neuropsychopharmacology, Vol.65, pp.15-29
2022
PMID: 36206584
Appears in Thompson Institute Research Collection
Abstract
The experience of stress is often utilised in models of emerging mental illness and neurobiological systems are implicated as the intermediary link between the experience of psychological stress and the development of a mental disorder. Chronic stress and prolonged glucocorticoid exposure have potent effects on neuronal architecture particularly in regions that modulate the hypothalamic pituitary adrenal (HPA) axis and are commonly associated with psychiatric disorders. This review provides an overview of stress modulating neurobiological and neurochemical systems which underpin stress related structural and functional brain changes. These changes are thought to contribute not only to the development of disorders, but also to the treatment resistance and chronicity seen in some of our most challenging mental disorders. Reports to date suggest that stress related psychopathology is the aetiological mechanism of these disorders and thus we review the rapid acting antidepressant ketamine as an effective emerging treatment. Ketamine, an N methyl D aspartate (NMDA) receptor antagonist, is shown to induce a robust treatment effect in mental disorders via enhanced synaptic strength and connectivity in key brain regions. Whilst ketamine's glutamatergic effect has been previously examined, we further consider ketamine's capacity to modulate the HPA axis and associated pathways.
Details
- Title
- Stress, mental disorder and ketamine as a novel, rapid acting treatment
- Authors
- Megan Dutton (Corresponding Author) - University of the Sunshine Coast, Queensland, Thompson InstituteAdem Can (Author) - University of the Sunshine Coast, Queensland, Thompson InstituteJim Lagopoulos (Author) - University of the Sunshine Coast, Queensland, Thompson InstituteDaniel Hermens (Author) - University of the Sunshine Coast, Queensland, Thompson Institute
- Publication details
- European Neuropsychopharmacology, Vol.65, pp.15-29
- Publisher
- Elsevier BV
- Date published
- 2022
- DOI
- 10.1016/j.euroneuro.2022.09.006
- ISSN
- 1873-7862
- PMID
- 36206584
- Organisation Unit
- Thompson Institute
- Language
- English
- Record Identifier
- 99678896602621
- Output Type
- Journal article
Metrics
99 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Web Of Science research areas
- Clinical Neurology
- Neurosciences
- Pharmacology & Pharmacy
- Psychiatry
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: SDGs from InCites